Cyclin D1–CDK4/6 phosphorylates GTSE1 in cancer cells, preventing its degradation and sustaining high levels across the cell cycle, which enhances proliferation and correlates with poor prognosis.

Cell crowding causes high-grade breast cancer cells to become more invasive by activating a molecular switch that causes the cells to shrink and spread.

The global Cell Based Assays Market, valued at US$17.29 billion in 2024, is forecasted to grow at a robust CAGR of 9.1%, reaching US$17.84 billion in 2025 and an impressive US$27.55 billion by 2030.

This collaboration aims to enhance AI-driven phenotypic profiling in high-throughput cell-based assays. SANTA BARBARA, Calif., April 18, 2025 /PRNewswire-PRWeb/ -- ViQi, Inc. and Araceli ...